Sona Nanotech CEO David Regan and CMO Dr. Carman Giacomantonio discuss the science, results, and next steps for Targeted Hyperthermia Therapy, a novel, nanoparticle-based approach showing promising results in late-stage melanoma.
Sona Nanotech CEO David Regan and CMO Dr. Carman Giacomantonio discuss the science, results, and next steps for Targeted Hyperthermia Therapy, a novel, nanoparticle-based approach showing promising results in late-stage melanoma.